Claims
- 1. A cross-linkable monomer comprising:
a fumaric acid functional group having a first end and a second end; a first spacer group affixed to said first end and comprising at least one ethylene glycol repeating unit; a first terminal group affixed to said first spacer group; a second spacer group affixed to said second end and comprising at least one ethylene glycol repeating unit; and a second terminal group affixed to said second spacer group.
- 2. The composition according to claim 1 wherein said first and second spacer groups comprise the same number of ethylene glycol repeating units.
- 3. The composition according to claim 1 wherein said first and second terminal groups are each selected from the group consisting of protein fragments, whole proteins, carbohydrates, plasmid DNA, amino acids, amino acid derivatives, and peptide sequences.
- 4. The composition according to claim 3 wherein said first and second terminal groups are the same.
- 5. The composition according to claim 3 wherein said first and second terminal groups are different.
- 6. The composition according to claim 5 wherein one of said first and second terminal groups is selected to have a positive charge and the other of said first and second terminal groups is selected to enhance cell adhesion.
- 7. The composition according to claim 1 wherein one of said first and second terminal groups comprises agmatine.
- 8. The composition according to claim 1 wherein one of said first and second terminal groups comprises a bioactive molecule.
- 9. A hydrogel formed by cross-linking the monomer of claim 1.
- 10. A hydrogel comprising a unsaturated monomer or macromer cross-linked with the monomer of claim 1.
- 11. A hydrogel comprising a fumarate-based polyester modified with agmatine.
- 12. A hydrogel comprising a unsaturated monomer or macromer cross-linked with a fumarate-based macromer or monomer.
- 13. A hydrogel according to claim 12 wherein the fumarate-based macromer or monomer comprises P(PF-co-EG).
- 14. The hydrogel according to claim 12 wherein the Agm-PEGF content of the composition is at least 0.1 mg/g of P(PF-co-EG).
- 15. The hydrogel according to claim 13 wherein the Agm-PEGF content of the composition is at least 0.7 mg/g of P(PF-co-EG).
- 16. A method for forming a hydrogel, comprising the steps of:
a) synthesizing a copolymer of poly(propylene fumarate) (PPF) and poly(ethylene glycol (PEG) so as to produce P(PF-co-EG); b) synthesizing a PEG-tethered fumarate (PEGF); c) coupling agmatine sulfate to the PEGF to produce PEGF modified with agmatine (Agm-PEGF); and d) cross-linking the P(PF-co-EG) from step a) with Agm-PEGF from step c).
- 17. The method according to claim 14 wherein step d) is carried out in vivo.
- 18. A carrier for cells, drugs, or genes, comprising a hydrogel comprising a fumarate-based polyester modified with agmatine.
- 19. A method for forming a hydrogel, comprising the steps of:
a) synthesizing a copolymer of poly(propylene fumarate) (PPF) and a diol repeating unit (R) so as to produce P(PF-co-R); b) synthesizing a poly(R)-tethered fumarate (PRF); c) coupling at least one terminal group X to the PRF to produce PRF modified with X (X-PRF); and d) cross-linking P(PF-co-R) from step a) with X-PRF from step c).
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of U.S. provisional applications No. 60/331,668, filed on Nov. 20, 2001, and entitled “Crosslinkable Compounds With Guanidino Groups” and No. 60/375,270, filed on Apr. 24, 2002, and entitled “Synthesis and Characterization of Biodegradable Cationic Poly(propylene fumarate-co-ethylene glycol) Copolymer Hydrogels Modified with Agmatine for Enhanced Cell Adhesion,” each of which is incorporated herein in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] Research leading to the present invention was supported in part by the federal government under Grant No. RO1-DE13031 awarded by the National Institutes of Health. The United States government may have certain rights in the invention.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60375270 |
Apr 2002 |
US |
|
60331668 |
Nov 2001 |
US |